Semaglutide for weight loss: what Ozempic actually does

What did @dr.renatoandrade actually say?

Honestly, this is a difficult video to fact-check in the traditional sense. The transcript provided is largely incoherent, consisting of fragmented, disconnected phrases that do not form clear medical claims. Lines like "the socialiest words to make you happy" and "whenever you project a city, you can do more than once a day in your life" do not map onto any identifiable medical argument about semaglutide or diabetes treatment.

What we can work with is the caption and hashtag framing, which positions this video as an explainer on semaglutide (Ozempic) as a diabetes drug that "helps with weight loss." That framing is, at minimum, directionally correct and worth addressing seriously, even if the spoken content does not hold up to scrutiny.

Does the science back this up?

The core premise, that semaglutide is a diabetes medication with meaningful weight loss effects, is well-supported by clinical evidence. This is not a fringe claim or influencer hype. It is the documented pharmacology of the drug.

Semaglutide is a GLP-1 receptor agonist approved by the FDA first for type 2 diabetes (Ozempic, 2017) and later at higher doses specifically for chronic weight management (Wegovy, 2021). The SUSTAIN trial series established its glucose-lowering efficacy. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that 2.4 mg weekly semaglutide produced an average body weight reduction of 14.9% over 68 weeks in adults with obesity but without diabetes. That is a clinically meaningful number, not a rounding error.

The mechanism is real. GLP-1 receptors in the hypothalamus regulate appetite signaling. Semaglutide slows gastric emptying, reduces hunger, and improves insulin secretion in a glucose-dependent manner. The hashtag grouping semaglutide with liraglutide (Saxenda) is also reasonable, as both are GLP-1 agonists used in weight management, though they differ in potency and dosing frequency.

What did they get wrong (or right)?

The video caption gets the basic category right: semaglutide is a diabetes drug that also produces weight loss. That framing reflects the actual clinical history of the molecule. Credit where it is due.

However, the spoken transcript contains no extractable medical claims at all. That is its own problem. A video with 78,800 views presented as a medical explainer, with a physician handle, should be delivering accurate and coherent information. When the verbal content is disconnected from the medical topic entirely, viewers are receiving exactly zero clinical education, regardless of what the caption promises.

There is also a meaningful omission issue. The caption lumps Saxenda (liraglutide) and Ozempic (semaglutide) together without noting they are different drugs with different approvals, dosing schedules, and efficacy profiles. Semaglutide at 2.4 mg outperformed liraglutide 3 mg in head-to-head data (Rubino et al., 2022, JAMA). Treating them as interchangeable is not accurate.

• Semaglutide and liraglutide are both GLP-1 agonists but are not the same drug
• Dosing and approval indications differ significantly between the two
• No compounded version of semaglutide should be assumed equivalent to FDA-approved formulations

What should you actually know?

If you found this video while researching semaglutide for diabetes or weight loss, here is what the evidence actually supports, regardless of what was said on screen.

Semaglutide (brand names Ozempic and Wegovy) is one of the most studied weight-management drugs in recent history. The STEP program trials and SELECT trial (Lincoff et al., 2023, NEJM) showed cardiovascular event reduction in people with obesity and established cardiovascular disease, which is a significant finding beyond just weight and glucose numbers.

That said, it is a prescription drug with real side effects. Nausea, vomiting, and gastrointestinal discomfort are common, particularly during dose escalation. Rare but serious risks include pancreatitis and, based on rodent studies, a theoretical concern for thyroid C-cell tumors, which is why it carries a boxed warning. These are not reasons to avoid it if clinically indicated, but they are reasons to have an actual conversation with a licensed prescriber rather than making decisions based on a TikTok caption.

Semaglutide does not cure diabetes or obesity. It manages them, effectively, in the right candidates. That distinction matters both clinically and legally.